Sign In  |  Register  |  About Pleasanton  |  Contact Us

Pleasanton, CA
September 01, 2020 1:32pm
7-Day Forecast | Traffic

  • Search Hotels in Pleasanton

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Enanta Pharmaceuticals, Inc. - Common Stock (NQ: ENTA )

6.280 +0.420 (+7.17%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Enanta Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2021 with Webcast and Conference Call Today at 4:30 p.m. ET
From Enanta Pharmaceuticals, Inc.
Via Business Wire
52 Biggest Movers From Friday
Gainers Greenland Technologies Holding Corporation (NASDAQ: GTEC) shares surged 90.2% to close at $9.89 on Friday. Greenland Technologies highlighted the launch of second... 
Via Benzinga
Expert Ratings For Enanta Pharmaceuticals
Enanta Pharmaceuticals (NASDAQ:ENTA) has observed the following analyst ra... 
Via Benzinga
Earnings Scheduled For November 22, 2021
Companies Reporting Before The Bell • Cerence (NASDAQ:CRNC) is estimated to report quarterly earnings at $0.56 per share on revenue of $97.92 million. • Avaya... 
Via Benzinga
The Week Ahead In Biotech (Nov. 21-Nov. 27): FDA Decisions, Earnings In The Spotlight In Holiday-Shortened Week
Biotech stocks showed a lack of direction in the week ending Nov. 19 before finishing modestly higher. Stocks did not have much meaningful catalysts to react to amid the winding down of the reporting... 
Via Talk Markets
Exposures Product Safety
The Week Ahead In Biotech (Nov. 21-Nov. 27): Takeda, Aadi, Fennec FDA Decisions, Earnings In The Spotlight In Holiday-Shortened Week
Biotech stocks showed a lack of direction in the week ending Nov. 19 before finishing modestly higher. Stocks did not have much meaningful catalysts to react to amid the... 
Via Benzinga
Exposures Product Safety
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers SCYNEXIS (NASDAQ:SCYX) stock rose 15.69% to $7.15 during Friday's regular session. As of 12:30 EST, this security is trading at a volume of 1.2 million shares... 
Via Benzinga
Enanta Pharmaceuticals's Earnings: A Preview
Enanta Pharmaceuticals (NASDAQ:ENTA) is set to give its latest quarterly earnings report on Monday, 2021-11-22. Here's what investors need to know before the announcement.... 
Via Benzinga
The Daily Biotech Pulse: Connect Biopharma Sinks On Eczema Drug Readout, Enanta Pulls Plug On HBV Drug, Clinical Setback For Merck In HIV Trial
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Connect Biopharma Atopic Dermatitis Treatment Aces Mid-stage Study But Lack... 
Via Benzinga
Safety Signals Force Enanta To Stop EDP-721 HBV Program
Enanta Pharmaceuticals Inc (NASDAQ: ENTA) has decided to discontinue the development of EDP-721, an oral Hepatitis B Virus (HBV) RNA destabilizer. The move follows... 
Via Benzinga
Enanta Pharmaceuticals to Participate in December Investor Conferences
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Enanta Pharmaceuticals Announces Update to its Hepatitis B Virus (HBV) Program
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Enanta Pharmaceuticals to Host Conference Call on November 22 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2021
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Enanta Pharmaceuticals Reports Positive Final Data from its Phase 1b Studies of EDP-514, a Novel Hepatitis B Virus Core Inhibitor
From Enanta Pharmaceuticals, Inc.
Via Business Wire
The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More
Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week. What was good news for Pfizer, Inc. (NYSE: PFE) turned out... 
Via Benzinga
10 Biggest Price Target Changes For Monday
Barclays cut Deciphera Pharmaceuticals, Inc. (NASDAQ: 
Via Benzinga
3 Explosive Biotech Stocks -- Could They Shoot Even Higher?
These biotech stocks have recently been responsible for a slew of rocketship emojis. 
Via The Motley Fool
What 7 Analyst Ratings Have To Say About Enanta Pharmaceuticals
Enanta Pharmaceuticals (NASDAQ:ENTA) has observed the following analyst ra... 
Via Benzinga
Enanta Plans To Start Human Trials For Its COVID-19 Candidate In 2022
Enanta Pharmaceuticals Inc (NASDAQ: ENTA) has reported new preclinical data for EDP-235, its recently announced lead oral protease inhibitor for COVID-19. ... 
Via Benzinga
Exposures COVID-19
Enanta Pharmaceuticals Presents New Data for EDP-235, its Lead Oral Protease Inhibitor Designed for the Treatment of COVID-19, at the ISIRV–WHO Virtual Conference 2021
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Where Enanta Pharmaceuticals Stands With Analysts
Analysts have provided the following ratings for Enanta Pharmaceuticals (NASDAQ: 
Via Benzinga
The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 11) AstraZeneca Plc (NASDAQ:... 
Via Benzinga
Exposures COVID-19
The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 7) Alkermes plc (NASDAQ: ALKS)... 
Via Benzinga
Exposures Product Safety
Benzinga's Top Ratings Upgrades, Downgrades For October 7, 2021
Upgrades For State Street Corporation (NYSE: 
Via Benzinga
New Preclinical Data for EDP-235, Enanta’s Oral Protease Inhibitor Specifically Designed for the Treatment of COVID-19, to be Presented at ISRIV-WHO Virtual 2021 Conference: COVID-19, Influenza and RSV: Surveillance-Informed Prevention and Treatment
From Enanta Pharmaceuticals, Inc.
Via Business Wire
The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 6) Enanta Pharmaceuticals, Inc... 
Via Benzinga
Enanta Pharmaceuticals to Present at the H.C. Wainwright 2nd Annual Hepatitis B Virus Virtual Conference
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Enanta To Discontinue Internal Development Of NASH Candidates
After looking at interim phase 2b data, Enanta Pharmaceuticals Inc (NASDAQ: ENTA) has decided to stop the monotherapy trial of EDP-305 for non-alcoholic... 
Via Benzinga
Enanta Pharmaceuticals Provides Update on NASH FXR Agonist Programs
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Enanta Pharmaceuticals Announces Data Presentations at AASLD’s The Liver Meeting® 2021
From Enanta Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photography by Christophe Tomatis
Copyright © 2010-2020 Pleasanton.com & California Media Partners, LLC. All rights reserved.